| Literature DB >> 15842954 |
Abstract
Therapeutic strategies based on the use of immunostimulatory sequences of DNA containing a CpG motif (also known as ISS DNA, or CpG DNA) are focused on minimizing the allergenicity of immunotherapy while improving its effectiveness. Several ISS DNA-based methods of immunization (ISS DNA alone, ISS DNA conjugated to a protein allergen) have shown promise in animal models of asthma, and some of these ISS DNA-based therapies have entered clinical trials. These ongoing clinical trials will help to determine whether any of these ISS DNA-based therapies are safe and effective to use in subjects with allergic rhinitis and asthma.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15842954 DOI: 10.1007/s11882-005-0035-7
Source DB: PubMed Journal: Curr Allergy Asthma Rep ISSN: 1529-7322 Impact factor: 4.919